INVERSINE Drug Patent Profile
✉ Email this page to a colleague
When do Inversine patents expire, and when can generic versions of Inversine launch?
Inversine is a drug marketed by Targacept and is included in one NDA.
The generic ingredient in INVERSINE is mecamylamine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inversine
A generic version of INVERSINE was approved as mecamylamine hydrochloride by LGM PHARMA on March 19th, 2013.
Summary for INVERSINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Clinical Trials: | 6 |
Patent Applications: | 490 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INVERSINE at DailyMed |
Recent Clinical Trials for INVERSINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yale University | Phase 3 |
National Alliance for Research on Schizophrenia and Depression | Phase 3 |
Autism Speaks | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for INVERSINE
US Patents and Regulatory Information for INVERSINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Targacept | INVERSINE | mecamylamine hydrochloride | TABLET;ORAL | 010251-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |